
    
      The purpose is to:

        1. Assess the single-dose pharmacokinetic (PK) parameters of lorcaserin and a primary
           metabolites (M1 and M5) in obese adolescent subjects ages 12-17 (inclusive)

        2. Assess the safety and tolerability of a single oral dose of lorcaserin in obese
           adolescent subjects ages 12-17 (inclusive)
    
  